2025 France Amyotrophic Lateral Sclerosis (Als) Treatment Revenue Opportunities Report
Description
The 2025 France Amyotrophic Lateral Sclerosis (Als) Treatment Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Amyotrophic Lateral Sclerosis (ALS) Treatment by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in ALS treatment in France are Sanofi, ILTOO Pharma, Amylyx Pharmaceuticals, and Axoltis Pharma. Sanofi, a major French pharmaceutical company, leads with its ALS treatment riluzole (Rilutek), which is approved worldwide and has proven to modestly prolong survival in ALS patients. ILTOO Pharma, based in Paris, recently signed a license agreement to develop low-dose interleukin-2 for ALS, stemming from the MIROCALS European research consortium, demonstrating strong academic-industrial collaboration within France. Amylyx Pharmaceuticals obtained compassionate access approval from French regulators for AMX0035 (RELYVRIO/ALBRIOZA), an investigational combination drug showing promise in ALS therapy. Axoltis Pharma, a French biotech, is advancing a neuroprotective peptide candidate, NX210c, currently in phase 2 trials focusing on blood-brain barrier repair and neuroprotection in ALS.
These companies represent a mix of established pharmaceutical giants and innovative biotechs driving ALS treatment research and development in France. Sanofi holds a significant portion of the market with its long-standing riluzole product, while ILTOO Pharma harnesses European-funded clinical trial data to develop novel immunotherapies. Amylyx actively works with French health authorities for therapy access, showcasing regulatory progress. Axoltis Pharma is notable for its translational approach addressing early ALS pathology via peptide therapy. Together, they illustrate the vibrant ALS treatment ecosystem in France combining clinical care, cutting-edge research, and translational development with global and European ties.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Amyotrophic Lateral Sclerosis (ALS) Treatment by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in ALS treatment in France are Sanofi, ILTOO Pharma, Amylyx Pharmaceuticals, and Axoltis Pharma. Sanofi, a major French pharmaceutical company, leads with its ALS treatment riluzole (Rilutek), which is approved worldwide and has proven to modestly prolong survival in ALS patients. ILTOO Pharma, based in Paris, recently signed a license agreement to develop low-dose interleukin-2 for ALS, stemming from the MIROCALS European research consortium, demonstrating strong academic-industrial collaboration within France. Amylyx Pharmaceuticals obtained compassionate access approval from French regulators for AMX0035 (RELYVRIO/ALBRIOZA), an investigational combination drug showing promise in ALS therapy. Axoltis Pharma, a French biotech, is advancing a neuroprotective peptide candidate, NX210c, currently in phase 2 trials focusing on blood-brain barrier repair and neuroprotection in ALS.
These companies represent a mix of established pharmaceutical giants and innovative biotechs driving ALS treatment research and development in France. Sanofi holds a significant portion of the market with its long-standing riluzole product, while ILTOO Pharma harnesses European-funded clinical trial data to develop novel immunotherapies. Amylyx actively works with French health authorities for therapy access, showcasing regulatory progress. Axoltis Pharma is notable for its translational approach addressing early ALS pathology via peptide therapy. Together, they illustrate the vibrant ALS treatment ecosystem in France combining clinical care, cutting-edge research, and translational development with global and European ties.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
